MDRNA Inc. is making good on its plan to maximize its shelved nasal programs, with the FDA's approval of a generic nasal spray for osteoporosis that has been launched by Par Pharmaceutical Cos. Inc. (BioWorld Today)

Celldex Therapeutics Inc. took another step toward expanding its pipeline, agreeing to buy CuraGen Corp. in a $94.5 million stock deal that will bring in 11 drug candidates and some added cash. (BioWorld Today)